Adrian Toutoungi

Adrian is a seasoned IP lawyer who relishes immersing himself in his client’s technology, product roadmap and patent/IP strategy. He is regularly involved in the negotiation and drafting of technology licence agreements and other contracts with a heavy IP element, such as R&D collaborations, joint ventures, grant funding agreements and other commercial arrangements. He also advises on the EC and UK competition law aspects of these agreements, and issues relating to technical standardisation, essential IPR and patent pooling.

Adrian has a wealth of experience in handling the IP aspects of University spin-outs, IPOs and other major corporate transactions and disputes, including for FTSE 100 and Fortune 500 corporations. He is also a valued patent litigator, having recently advised on disputes involving pharmaceuticals, somatic cell therapy, semiconductor chip design, inkjet printing technology, digital compression algorithms, LCD flat-panel technology, telecoms and pharmaceuticals. He also frequently helps clients with disputes involving confidential information, database rights, trade marks, copyright and designs.

Adrian publishes and speaks regularly on a variety of intellectual property issues.

CV

Since 2019 Partner, Taylor Wessing

2007 - 2019 Partner, Eversheds Sutherland LLP

2007 Counsel, Boyes Turner

Karriere

Since 2019 Partner, Taylor Wessing

2007 - 2019 Partner, Eversheds Sutherland LLP

2007 Counsel, Boyes Turner

Ausbildung

2000 Post-Graduate Diploma, Intellectual Property Law and Practice, University of Bristol

1997 Bachelor of Laws, European Law, College of Europe, Bruges

1994 Master of Arts, Physics (First Class Honours), University of Oxford

Mitgliedschaften

The International Association for the Protection of Intellectual Property

The European Patent Lawyers Association

Awards

Legal 500 UK 2026

Featured

Legal 500 UK 2025

Managing Intellectual Property – IP Stars 2024

Chambers and Partners UK 2024

Mehr

Experience

Advising on Draig Therapeutics' US$140 million series A financing

We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.

Press release

Ross McNaughton

Elinor Picton

Oli Denne

Helen Farr

Adrian Toutoungi

Charlie Adams

Nicholas Vollers

Ed Chapman

Market-leading work in the life sciences sector

We have won Life Sciences Team of the Year at the Legal Business Awards 2023 for advising on three simultaneous transformational transactions for AIM-listed Shield Therapeutics plc.

Press release

Shane Gleghorn

Andrew Edge

Adrian Toutoungi